These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31899769)

  • 1. Development of a risk score for prediction of poor treatment outcomes among patients with multidrug-resistant tuberculosis.
    Alene KA; Viney K; Gray DJ; McBryde ES; Xu Z; Clements ACA
    PLoS One; 2020; 15(1):e0227100. PubMed ID: 31899769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis.
    Alene KA; Viney K; Yi H; McBryde ES; Yang K; Bai L; Gray DJ; Xu Z; Clements ACA
    PLoS One; 2018; 13(5):e0197880. PubMed ID: 29791488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia.
    Shibabaw A; Gelaw B; Wang SH; Tessema B
    PLoS One; 2018; 13(6):e0198080. PubMed ID: 29944658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.
    Alene KA; Viney K; McBryde ES; Tsegaye AT; Clements AC
    Trop Med Int Health; 2017 Mar; 22(3):351-362. PubMed ID: 27978594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
    Woldeyohannes D; Assefa T; Aman R; Tekalegn Y; Hailemariam Z
    PLoS One; 2019; 14(10):e0224025. PubMed ID: 31665154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
    Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.
    Chien JY; Chien ST; Chiu WY; Yu CJ; Hsueh PR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4708-16. PubMed ID: 27216062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
    Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
    Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study.
    Kassa GM; Teferra AS; Wolde HF; Muluneh AG; Merid MW
    BMC Infect Dis; 2019 Sep; 19(1):817. PubMed ID: 31533661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia.
    Mekonnen F; Tessema B; Moges F; Gelaw A; Eshetie S; Kumera G
    BMC Infect Dis; 2015 Oct; 15():461. PubMed ID: 26503269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.
    Kurbatova EV; Gammino VM; Bayona J; Becerra MC; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Taylor A; Viiklepp P; Zignol M; Cegielski JP
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1335-43. PubMed ID: 23107633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia.
    Demile B; Zenebu A; Shewaye H; Xia S; Guadie A
    BMC Infect Dis; 2018 May; 18(1):249. PubMed ID: 29855354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
    BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).
    Kateete DP; Kamulegeya R; Kigozi E; Katabazi FA; Lukoye D; Sebit SI; Abdi H; Arube P; Kasule GW; Musisi K; Dlamini MG; Khumalo D; Joloba ML
    BMC Pulm Med; 2019 Jul; 19(1):124. PubMed ID: 31291943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study.
    Meressa D; Hurtado RM; Andrews JR; Diro E; Abato K; Daniel T; Prasad P; Prasad R; Fekade B; Tedla Y; Yusuf H; Tadesse M; Tefera D; Ashenafi A; Desta G; Aderaye G; Olson K; Thim S; Goldfeld AE
    Thorax; 2015 Dec; 70(12):1181-8. PubMed ID: 26506854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk screening and detection of multidrug-resistant tuberculosis in two prefectures of China: a drug susceptibility surveillance-based secondary data analysis.
    Yang Z; Zhou C; Ning Z; Lu W; Zhao Q; Hu Y; Diwan VK; Xu B
    Glob Health Action; 2018; 11(1):1500763. PubMed ID: 30203719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.